95 related articles for article (PubMed ID: 28855436)
21. Long glucocorticoid-induced leucine zipper regulates human thyroid cancer cell proliferation.
Ayroldi E; Petrillo MG; Marchetti MC; Cannarile L; Ronchetti S; Ricci E; Cari L; Avenia N; Moretti S; Puxeddu E; Riccardi C
Cell Death Dis; 2018 Feb; 9(3):305. PubMed ID: 29467389
[TBL] [Abstract][Full Text] [Related]
22. Effects of forskolin on Kupffer cell production of interleukin-10 and tumor necrosis factor alpha differ from those of endogenous adenylyl cyclase activators: possible role for adenylyl cyclase 9.
Dahle MK; Myhre AE; Aasen AO; Wang JE
Infect Immun; 2005 Nov; 73(11):7290-6. PubMed ID: 16239525
[TBL] [Abstract][Full Text] [Related]
23. Sorafenib controls the epithelial‑mesenchymal transition of ovarian cancer cells via EGF and the CD44‑HA signaling pathway in a cell type‑dependent manner.
Park GB; Ko HS; Kim D
Mol Med Rep; 2017 Aug; 16(2):1826-1836. PubMed ID: 28627617
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of MAPK and VEGFR by Sorafenib Controls the Progression of Endometriosis.
Leconte M; Santulli P; Chouzenoux S; Marcellin L; Cerles O; Chapron C; Dousset B; Batteux F
Reprod Sci; 2015 Sep; 22(9):1171-80. PubMed ID: 26169036
[TBL] [Abstract][Full Text] [Related]
25. Differential involvement of signaling pathways in the regulation of growth hormone release by somatostatin and growth hormone-releasing hormone in orange-spotted grouper (Epinephelus coioides).
Wang B; Qin C; Zhang C; Jia J; Sun C; Li W
Mol Cell Endocrinol; 2014 Feb; 382(2):851-9. PubMed ID: 24183819
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of extracellular signal-regulated kinase activity by sorafenib increases sensitivity to DNR in K562 cells.
Xiao RZ; He CM; Xiong MJ; Ruan XX; Wang LL; Chen Y; Lin DJ
Oncol Rep; 2013 May; 29(5):1895-901. PubMed ID: 23467984
[TBL] [Abstract][Full Text] [Related]
27. The effects of lysophosphatidate on thyrotropin-mediated differentiated thyroid function in FRTL-5 thyroid cells.
Das S; Devlin M; Brindley DN; Ginsberg J
Thyroid; 1999 Jun; 9(6):621-6. PubMed ID: 10411126
[TBL] [Abstract][Full Text] [Related]
28. Mechanisms for luteinizing hormone induction of growth hormone gene transcription in fish model: crosstalk of the cAMP/PKA pathway with MAPK-and PI3K-dependent cascades.
Sun C; He M; Ko WK; Wong AO
Mol Cell Endocrinol; 2014 Feb; 382(2):835-50. PubMed ID: 24161589
[TBL] [Abstract][Full Text] [Related]
29. Gonadotropin-stimulated epidermal growth factor receptor expression in human ovarian surface epithelial cells: involvement of cyclic AMP-dependent exchange protein activated by cAMP pathway.
Choi JH; Chen CL; Poon SL; Wang HS; Leung PC
Endocr Relat Cancer; 2009 Mar; 16(1):179-88. PubMed ID: 19022848
[TBL] [Abstract][Full Text] [Related]
30. Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK-mTORC1 signaling.
Fumarola C; Caffarra C; La Monica S; Galetti M; Alfieri RR; Cavazzoni A; Galvani E; Generali D; Petronini PG; Bonelli MA
Breast Cancer Res Treat; 2013 Aug; 141(1):67-78. PubMed ID: 23963659
[TBL] [Abstract][Full Text] [Related]
31. Iodide- and glucose-handling gene expression regulated by sorafenib or cabozantinib in papillary thyroid cancer.
Ruan M; Liu M; Dong Q; Chen L
J Clin Endocrinol Metab; 2015 May; 100(5):1771-9. PubMed ID: 25768669
[TBL] [Abstract][Full Text] [Related]
32. Differentiation-induced alterations in cyclic AMP signaling in the Cath.a differentiated (CAD) neuronal cell line.
Johnston CA; Beazely MA; Bilodeau ML; Andrisani O; Watts VJ
J Neurochem; 2004 Mar; 88(6):1497-508. PubMed ID: 15009651
[TBL] [Abstract][Full Text] [Related]
33. Activation of MEK/ERK Signaling by PACAP in Guinea Pig Cardiac Neurons.
Clason TA; Girard BM; May V; Parsons RL
J Mol Neurosci; 2016 Jun; 59(2):309-16. PubMed ID: 27194157
[TBL] [Abstract][Full Text] [Related]
34. Cyclic AMP-mediated growth suppression and MAPK phosphorylation in thyroid papillary carcinoma cells.
Matsumoto H; Sakamoto A; Fujiwara M; Yano Y; Shishido-Hara Y; Fujioka Y; Kamma H
Mol Med Rep; 2008; 1(2):245-9. PubMed ID: 21479404
[TBL] [Abstract][Full Text] [Related]
35. Sorafenib and thyroid cancer.
Fallahi P; Ferrari SM; Santini F; Corrado A; Materazzi G; Ulisse S; Miccoli P; Antonelli A
BioDrugs; 2013 Dec; 27(6):615-28. PubMed ID: 23818056
[TBL] [Abstract][Full Text] [Related]
36. Cyclic AMP synergizes with butyrate in promoting β-defensin 9 expression in chickens.
Sunkara LT; Zeng X; Curtis AR; Zhang G
Mol Immunol; 2014 Feb; 57(2):171-80. PubMed ID: 24141182
[TBL] [Abstract][Full Text] [Related]
37. p38 mitogen-activated protein kinase contributes to cell cycle regulation by cAMP in FRTL-5 thyroid cells.
Corrèze C; Blondeau JP; Pomérance M
Eur J Endocrinol; 2005 Jul; 153(1):123-33. PubMed ID: 15994754
[TBL] [Abstract][Full Text] [Related]
38. Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells.
Pal HC; Baxter RD; Hunt KM; Agarwal J; Elmets CA; Athar M; Afaq F
Oncotarget; 2015 Sep; 6(29):28296-311. PubMed ID: 26299806
[TBL] [Abstract][Full Text] [Related]
39. MK2206 overcomes the resistance of human liver cancer stem cells to sorafenib by inhibition of pAkt and upregulation of pERK.
Zhai B; Zhang X; Sun B; Cao L; Zhao L; Li J; Ge N; Chen L; Qian H; Yin Z
Tumour Biol; 2016 Jun; 37(6):8047-55. PubMed ID: 26711788
[TBL] [Abstract][Full Text] [Related]
40. Targeted therapies in advanced differentiated thyroid cancer.
Carneiro RM; Carneiro BA; Agulnik M; Kopp PA; Giles FJ
Cancer Treat Rev; 2015 Sep; 41(8):690-8. PubMed ID: 26105190
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
